Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.29 -0.3%	$3.68	$1.24 ▼ $4.08	$874.98M	0.96	3.90 million shs	2.89 million shs
AMPH Amphastar Pharmaceuticals	$30.21 -0.9%	$23.67	$20.39 ▼ $53.96	$1.42B	0.76	626,533 shs	464,374 shs
COLL Collegium Pharmaceutical	$37.16 -1.8%	$31.39	$23.23 ▼ $42.29	$1.19B	0.68	375,312 shs	403,902 shs
MNPR Monopar Therapeutics	$35.86 +7.0%	$38.04	$2.15 ▼ $54.30	$206.76M	1.05	22,796 shs	30,434 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-0.60%	-12.93%	-16.88%	+29.92%	+146.27%
AMPH Amphastar Pharmaceuticals	+0.43%	+46.40%	+38.86%	+25.33%	-30.03%
COLL Collegium Pharmaceutical	-0.03%	+27.26%	+15.32%	+29.04%	+3.13%
MNPR Monopar Therapeutics	-6.66%	-17.56%	-23.37%	-15.27%	+1,273.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.0633 of 5 stars	3.6	2.0	4.0	3.1	0.8	0.6
AMPH Amphastar Pharmaceuticals	3.2005 of 5 stars	1.3	1.0	3.7	2.5	4.2	1.3
COLL Collegium Pharmaceutical	2.7384 of 5 stars	2.5	0.0	3.0	2.0	0.8	1.3
MNPR Monopar Therapeutics	3.0647 of 5 stars	3.4	4.0	0.0	3.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	105.17% Upside
AMPH Amphastar Pharmaceuticals	2.50	Moderate Buy	$31.50	4.27% Upside
COLL Collegium Pharmaceutical	3.00	Buy	$42.33	13.92% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	67.32% Upside

Current Analyst Ratings Breakdown

Latest MNPR, COLL, AKBA, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/12/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$36.00
8/11/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$44.00
8/8/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	5.45	N/A	N/A	$0.11 per share	29.91
AMPH Amphastar Pharmaceuticals	$731.97M	1.92	$4.96 per share	6.09	$16.29 per share	1.85
COLL Collegium Pharmaceutical	$631.45M	1.85	$12.10 per share	3.07	$7.37 per share	5.04
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$8.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.17	N/A	N/A	N/A	-17.91%	N/A	-13.47%	N/A
AMPH Amphastar Pharmaceuticals	$159.52M	$2.67	11.31	9.18	N/A	18.64%	20.76%	9.68%	N/A
COLL Collegium Pharmaceutical	$69.19M	$1.04	35.73	6.17	N/A	5.13%	97.28%	13.87%	N/A
MNPR Monopar Therapeutics	-$15.59M	-$3.33	N/A	N/A	N/A	N/A	-41.76%	-39.49%	8/15/2025 (Estimated)

Latest MNPR, COLL, AKBA, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	MNPR Monopar Therapeutics	-$0.47	-$0.35	+$0.12	-$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.61	1.98	1.84
AMPH Amphastar Pharmaceuticals	0.80	3.29	2.21
COLL Collegium Pharmaceutical	3.27	1.18	1.10
MNPR Monopar Therapeutics	N/A	33.93	36.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
AMPH Amphastar Pharmaceuticals	65.09%
COLL Collegium Pharmaceutical	N/A
MNPR Monopar Therapeutics	1.83%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
AMPH Amphastar Pharmaceuticals	27.50%
COLL Collegium Pharmaceutical	2.51%
MNPR Monopar Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	265.14 million	257.19 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	46.49 million	33.71 million	Optionable
COLL Collegium Pharmaceutical	210	31.50 million	30.71 million	Optionable
MNPR Monopar Therapeutics	10	6.17 million	4.86 million	Not Optionable

MNPR, COLL, AKBA, and AMPH Headlines

Recent News About These Companies

Monopar Therapeutics (NASDAQ:MNPR) Announces Earnings Results, Beats Expectations By $0.12 EPS

August 13 at 2:29 PM | marketbeat.com

Monopar Therapeutics Inc.: Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 13 at 12:24 PM | finanznachrichten.de

Monopar Therapeutics Reports Increased R&D Expenses

August 13 at 7:23 AM | msn.com

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 12 at 4:22 PM | manilatimes.netM

Monopar Therapeutics Inc. Reports Q2 2025 Financial Results and Progress on ALXN1840 and MNPR-101 Clinical Trials

August 12 at 9:00 AM | quiverquant.comQ

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 12 at 8:00 AM | globenewswire.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of "Moderate Buy" from Analysts

August 12 at 2:43 AM | marketbeat.com

Monopar Therapeutics (MNPR) Projected to Post Earnings on Friday

August 1, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Moderate Buy" from Analysts

July 18, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Sells $356,160.00 in Stock

July 17, 2025 | marketbeat.com

Christopher M. Starr Sells 16,800 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

July 17, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) CEO Sells $672,000.00 in Stock

July 17, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim R. Tsuchimoto Sells 8,904 Shares

July 17, 2025 | insidertrades.com

Cantor Fitzgerald Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight Recommendation

July 8, 2025 | msn.com

Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

June 26, 2025 | finance.yahoo.com

Institutional investors own a significant stake of 29% in Monopar Therapeutics Inc. (NASDAQ:MNPR)

June 23, 2025 | finance.yahoo.com

Chardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation

June 23, 2025 | msn.com

Monopar Therapeutics Inc.: Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | finanznachrichten.de

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know

June 11, 2025 | zacks.com

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | globenewswire.com

Monopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%

June 3, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MNPR, COLL, AKBA, and AMPH Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.29 -0.01 (-0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$3.31 +0.02 (+0.61%)

As of 07:57 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Amphastar Pharmaceuticals NASDAQ:AMPH

$30.21 -0.27 (-0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$30.28 +0.06 (+0.22%)

As of 07:11 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Collegium Pharmaceutical NASDAQ:COLL

$37.16 -0.70 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$37.26 +0.11 (+0.28%)

As of 06:12 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Monopar Therapeutics NASDAQ:MNPR

$35.86 +2.35 (+7.01%)

Closing price 04:00 PM Eastern

Extended Trading

$36.31 +0.45 (+1.25%)

As of 05:37 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time